The latest trading day saw Moderna (MRNA) settling at $27.19, representing a -0.75% change from its previous close.

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

A bull market will eventually follow the challenging and volatile times we face, and, based on history, this bull run is ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in Moderna to expedite the creation of a ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...

SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

Check Out Our Latest Stock Analysis on MRNA Moderna Price Performance Shares of MRNA opened at $25.74 on Wednesday. The firm’s 50 day moving average is $30.61 and its 200-day moving average is ...